Neutralizing and Other Antiviral Antibodies in HIV-1 Infection and Vaccination

Overview

Journal Curr Opin HIV AIDS

Specialty Infectious Diseases

Date 2009 Apr 18

PMID 19372883

Citations 13

Authors

David C Montefiori

Lynn Morris

Guido Ferrari

John R Mascola

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: New findings continue to support the notion that broadly crossreactive neutralizing antibody induction is a worthwhile and achievable goal for HIV-1 vaccines. Immunogens are needed that can overcome the genetic variability and complex immune evasion tactics of the virus. Other antibodies might bridge innate and acquired immunity for possible beneficial vaccine effects. This review summarizes progress made over the past year that has enhanced our understanding of humoral immunity as it relates to HIV-1 vaccine development.

Recent Findings: Although a clear path to designing an effective neutralizing antibody-based HIV-1 vaccine remains elusive, there is new information on how antibodies neutralize HIV-1, the epitopes involved, and clues to the possible nature of protective immunogens that keep this goal alive. Moreover, there is a greater understanding of HIV-1 diversity and its possible limits under immune pressure. Other antibodies might possess antiviral activity by mechanisms involving Fc receptor engagement or complement activation that would be of value for HIV-1 vaccines.

Summary: Recent developments strengthen the rationale for antibody-based HIV-1 vaccine immunogens and provide a stronger foundation for vaccine discovery.

Citing Articles

Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities.

Timofeeva A, Sedykh S, Nevinsky G Vaccines (Basel). 2022; 10(3).

PMID: 35335016 PMC: 8955465. DOI: 10.3390/vaccines10030384.

Pathogenic Correlates of Simian Immunodeficiency Virus-Associated B Cell Dysfunction.

Brocca-Cofano E, Kuhrt D, Siewe B, Xu C, Haret-Richter G, Craigo J J Virol. 2017; 91(23).

PMID: 28931679 PMC: 5686751. DOI: 10.1128/JVI.01051-17.

Natural infection as a blueprint for rational HIV vaccine design.

van Haaren M, van den Kerkhof T, van Gils M Hum Vaccin Immunother. 2016; 13(1):229-236.

PMID: 27649455 PMC: 5287307. DOI: 10.1080/21645515.2016.1232785.

Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens.

Sattentau Q Vaccines (Basel). 2015; 1(4):497-512.

PMID: 26344344 PMC: 4494206. DOI: 10.3390/vaccines1040497.

HIV therapeutic vaccines: moving towards a functional cure.

Mylvaganam G, Silvestri G, Amara R Curr Opin Immunol. 2015; 35:1-8.

PMID: 25996629 PMC: 4553139. DOI: 10.1016/j.coi.2015.05.001.

References

Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B . Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol. 2005; 79(10):6528-31. PMC: 1091724. DOI: 10.1128/JVI.79.10.6528-6531.2005. View

Gomez-Roman V, Patterson L, Venzon D, Liewehr D, Aldrich K, Florese R . Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol. 2005; 174(4):2185-9. DOI: 10.4049/jimmunol.174.4.2185. View

Huber M, Fischer M, Misselwitz B, Manrique A, Kuster H, Niederost B . Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med. 2006; 3(11):e441. PMC: 1637124. DOI: 10.1371/journal.pmed.0030441. View

Smith D, Strain M, Frost S, Pillai S, Wong J, Wrin T . Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology. 2006; 355(1):1-5. DOI: 10.1016/j.virol.2006.08.009. View

Ferrantelli F, Buckley K, Rasmussen R, Chalmers A, Wang T, Li P . Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. Virology. 2006; 358(1):69-78. DOI: 10.1016/j.virol.2006.07.056. View

Aasa-Chapman M, Holuigue S, Aubin K, Wong M, Jones N, Cornforth D . Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J Virol. 2005; 79(5):2823-30. PMC: 548453. DOI: 10.1128/JVI.79.5.2823-2830.2005. View

Derby N, Kraft Z, Kan E, Crooks E, Barnett S, Srivastava I . Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and.... J Virol. 2006; 80(17):8745-62. PMC: 1563892. DOI: 10.1128/JVI.00956-06. View

Binley J, Trkola A, Ketas T, Schiller D, CLAS B, Little S . The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. J Infect Dis. 2000; 182(3):945-9. DOI: 10.1086/315774. View

Donners H, Willems B, Beirnaert E, Colebunders R, Davis D, van der Groen G . Cross-neutralizing antibodies against primary isolates in African women infected with HIV-1. AIDS. 2002; 16(3):501-3. DOI: 10.1097/00002030-200202150-00030. View

10.

Brenchley J, Price D, Schacker T, Asher T, Silvestri G, Rao S . Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12(12):1365-71. DOI: 10.1038/nm1511. View

11.

Van Rompay K, Berardi C, Tarara R, Canfield D, Valverde C, Montefiori D . Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis. 1998; 177(5):1247-59. DOI: 10.1086/515270. View

12.

David A, Saez-Cirion A, Versmisse P, Malbec O, Iannascoli B, Herschke F . The engagement of activating FcgammaRs inhibits primate lentivirus replication in human macrophages. J Immunol. 2006; 177(9):6291-300. PMC: 2294445. DOI: 10.4049/jimmunol.177.9.6291. View

13.

Cham F, Zhang P, Heyndrickx L, Bouma P, Zhong P, Katinger H . Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity. Virology. 2005; 347(1):36-51. DOI: 10.1016/j.virol.2005.11.019. View

14.

Zhang M, Choudhry V, Sidorov I, Tenev V, Vu B, Choudhary A . Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. J Immunol Methods. 2006; 317(1-2):21-30. PMC: 1805821. DOI: 10.1016/j.jim.2006.09.016. View

15.

Choudhry V, Zhang M, Harris I, Sidorov I, Vu B, Dimitrov A . Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem Biophys Res Commun. 2006; 348(3):1107-15. PMC: 2268024. DOI: 10.1016/j.bbrc.2006.07.163. View

16.

Li M, Salazar-Gonzalez J, Derdeyn C, Morris L, Williamson C, Robinson J . Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol. 2006; 80(23):11776-90. PMC: 1642599. DOI: 10.1128/JVI.01730-06. View

17.

Mascola J . Defining the protective antibody response for HIV-1. Curr Mol Med. 2003; 3(3):209-16. DOI: 10.2174/1566524033479799. View

18.

Wu L, Yang Z, Xu L, Welcher B, Winfrey S, Shao Y . Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope. Vaccine. 2006; 24(23):4995-5002. DOI: 10.1016/j.vaccine.2006.03.083. View

19.

He B, Qiao X, Klasse P, Chiu A, Chadburn A, Knowles D . HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol. 2006; 176(7):3931-41. DOI: 10.4049/jimmunol.176.7.3931. View

20.

Richman D, Wrin T, Little S, Petropoulos C . Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003; 100(7):4144-9. PMC: 153062. DOI: 10.1073/pnas.0630530100. View